依碳酸氯替泼诺与双氯芬酸钠滴眼液对季节性过敏性结膜炎疗效比较

目的 比较依碳酸氯替泼诺滴眼液和双氯芬酸钠滴眼液治疗季节性过敏性结膜炎的有效性和安全性。 方法 季节性过敏性结膜炎病人44例，随机分为依碳酸氯替泼诺滴眼液组（A组）和双氯芬酸钠滴眼液组（B组），A、B组分别采用依碳酸氯替泼诺与双氯芬酸钠滴眼液每天点眼4次。根据用药后临床症状和体征进行疗效评价；并对治疗过程中所有不良事件进行记录。结果 治疗14 d后,A组结膜改变和眼部瘙痒程度改变的有效率为95.2%，B组为69.6%，两组有效率比较差异有显著性（χ2=4.86，P〈0.05）；A组畏光和分泌物消失占76.1%，B组占21.7%，两组比较差异有显著性（χ2=13.05，P〈0.01）。两组药物相关不良事件的发生情况比较差异无显著性（P〉0.05）。结论 依碳酸氯替泼诺滴眼液能明显缓解季节性过敏性结膜炎病人的临床症状, 治疗效果优于双氯芬酸钠滴眼液, 其安全性与双氯芬酸钠滴眼液类似。

A COMPARISON BETWEEN LOTEPREDNOL ETABONATE AND PRANOPROFEN EYE DROPS FOR VERNAL CONJUNCTIVITIS

Objective To compare the efficacy and safety of loteprednol etabonate and pranoprofen eye drops for patients with vernal conjunctivitis （VC）.Methods A total of 44 patients with VC were evenly divided randomized to group A （loteprednol etabonate group） and group B （pranoprofen group）. The eye drops were applied in the two groups accordingly,4 times a day. The efficacy and side effects were recorded. Results After 14 days of treatment, the effective rate of the changes of conjunctiva and ocular pruritus in group A group was 95.2%, that in group B was 69.6%, the difference between them was significant （χ2=4.86,P〈0.05） and the cure rate in group A was 76.1% and in group B was 21.7% in term of photophobia and secretion （χ2=13.05,P〈0.01）. The difference between the two groups was not significant in regard to drug-related adverse effects （P〉0.05）. Conclusion Loteprednol etabonate eye drops can effectively relieve clinical symptoms of vernal conjunctivitis, which is superior to pranoprofen eye drops and the adverse effects are similar.